Abstract
BRCA1/2
pathogenic variants have become associated with familial breast and ovarian cancers, and hereditary cancerāpredisposition syndrome. With advances in molecular biology,
BRCA
profiling facilitates early diagnosis and the implementation of preventive and therapeutic strategies.